

BRIEF COMMUNICATION OPEN



Assessing the digenic model in rare disorders using population sequencing data

Nerea Moreno-Ruiz ^{1,2,3}, Genomics England Research Consortium*, Oscar Lao ², Juan Ignacio Aróstegui ^{4,5}, Hafid Laayouni ^{2,6} and Ferran Casals ^{1,3,7} ✉

© The Author(s) 2022

An important fraction of patients with rare disorders remains with no clear genetic diagnosis, even after whole-exome or whole-genome sequencing, posing a difficulty in giving adequate treatment and genetic counseling. The analysis of genomic data in rare disorders mostly considers the presence of single gene variants in coding regions that follow a concrete monogenic mode of inheritance. A digenic inheritance, with variants in two functionally-related genes in the same individual, is a plausible alternative that might explain the genetic basis of the disease in some cases. In this case, digenic disease combinations should be absent or underrepresented in healthy individuals. We develop a framework to evaluate the significance of digenic combinations and test its statistical power in different scenarios. We suggest that this approach will be relevant with the advent of new sequencing efforts including hundreds of thousands of samples.

European Journal of Human Genetics (2022) 30:1439–1443; <https://doi.org/10.1038/s41431-022-01191-x>

INTRODUCTION

The percentage of genetically diagnosed cases of rare disorders has increased dramatically during the last decade, with a success rate estimated at 30–50% [1], although with important differences across disease types [2]. This percentage of success corresponds, almost entirely, to monogenic cases, the most probable model for rare genetic conditions. Many factors such as failure in identifying non-coding or structural variants in Whole Exome Sequencing (WES) studies, limitations in variant interpretation, epigenetics, mosaicism or the contribution of more than one gene may explain the remaining cases [3].

The digenic model is the simplest form of oligogenic disease [4], referring both to cases with a primary and a secondary *locus* (the first having greater contribution to the disease) and cases in which two functionally-related *loci* contribute with similar importance [5]. However, there are few reported examples of digenic inheritance [6]. The aim of this study is to develop an approach for assessing the digenic model by using population sequencing data, considering as digenic those cases in which variants in both genes are necessary to develop the disease. While the statistical power to detect gene interactions has been explored for common disorders [7], to our knowledge we still lack a framework to assess the detection capability of digenic combinations in rare disorders. We hypothesize that detrimental digenic combinations of alleles should not occur in the healthy population or should show lower frequencies than expected by chance, similarly to a monogenic recessive case where two pathogenic variants are not expected to

coexist *in trans* in a healthy individual. We evaluate the statistical power to detect causal digenic combinations considering different scenarios aiming to provide a new framework to analyze alternative models of inheritance in rare disorders.

METHODS

Statistical analysis

Two biallelic markers are considered. We denote genetic variant 1 (VAR1) with frequencies p_1 (A) and q_1 (a) and genetic variant 2 (VAR2) with frequencies p_2 (B) and q_2 (b). Individuals carrying the alternative allele (a/b) in one of the VARs of the digenic combination (VAR1/VAR2, respectively) are referred to as single carriers, while individuals carrying the alternative allele in both are named co-carriers (Supplementary Fig. S1). In our model, the observed number of co-carriers is calculated regardless of them being heterozygous/homozygous for the alternative allele for both of the variants, or homozygous for the alternative allele for one variant and heterozygous for the other. For each combination of VARs, a table with 4 genotype categories is built (Supplementary Table S1): (1) co-carriers, the category of interest for the digenic model (Aa/aa + Bb/bb); (2) single carriers for VAR1 (Aa/aa + BB); (3) single carriers for VAR2 (AA + Bb/bb) and (4) homozygous individuals for the reference allele for both variants (AA + BB).

The frequency of single carriers is calculated from the variant allele frequencies assuming Hardy-Weinberg Equilibrium (HWE) (Eqs. 1 and 2).

$$p(\text{Aa/aa}) = 2p_1q_1 + q_1^2 \quad (1)$$

$$p(\text{Bb/bb}) = 2p_2q_2 + q_2^2 \quad (2)$$

¹Servei de Genòmica, Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain. ²Institut de Biologia Evolutiva (UPF-CSIC), Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain. ³Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain. ⁴Departament d'Immunologia, Hospital Clínic - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. ⁵Escola de Medicina, Universitat de Barcelona, Barcelona, Spain. ⁶Bioinformatics Studies, ESCI-UPF, Barcelona, Spain. ⁷Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, Barcelona, Spain. *A list of authors and their affiliations appears at the end of the paper.

✉email: hafid.laayouni@upf.edu; ferrancasals@ub.edu

Received: 15 February 2022 Revised: 18 August 2022 Accepted: 8 September 2022

Published online: 3 October 2022




Fig. 1 Power analysis simulations performed with 1000 iterations for each set of parameters considering combination penetrance, allele frequency of the variants and sample size. The statistical power represents the percentage of significant results considering a significance of 0.05. Lighter colors represent the simulation results when genotype categories are not collapsed. **a**, statistical power as a function of digenic combination penetrance and allele frequency of the variants at a currently available sample size ($N = 38,341$). **b**, simulation results for a sample size of $N = 100,000$ individuals. **c**, simulation results for a sample size of $N = 500,000$ individuals. Red dashed line represents a statistical power of 80%.

From the frequency of single carriers, the expected number of individuals for each genotype category is calculated (Eqs. 3–6), with N being the total number of individuals:

$$(Aa/aa + Bb/bb) = p(Aa/aa) \times p(Bb/bb) \times N \tag{3}$$

$$(Aa/aa + BB) = p(Aa/aa) \times (1 - p(Bb/bb)) \times N \tag{4}$$

$$(AA + Bb/bb) = (1 - p(Aa/aa)) \times p(Bb/bb) \times N \tag{5}$$

$$(AA + BB) = (1 - p(Aa/aa)) \times (1 - p(Bb/bb)) \times N \tag{6}$$

To test if the observed counts adjust to the expected by random chance, a goodness of fit test following a Chi-squared (χ^2) distribution with 1 degrees of freedom is applied.

Power analysis

To assess the statistical power to detect deviations from random expectation in the number of co-carriers of digenic combinations, simulations are

performed generating a population at HWE. The number of co-carriers in the simulated population is reduced according to different penetrance values, being 1 for complete penetrance and values between 0 and 1 for incomplete penetrance. A certain penetrance, for example 0.2, would imply that 20% of co-carriers develop the disease and are absent in a control dataset, therefore a reduction of 20% in the number of co-carriers is applied by multiplying each category of co-carriers (aabb, Aabb, aaBb, AaBb) by 0.8 (1-penetrance). Frequencies of single carrier genotypes (AaBB, aaBB, AABb, AAAb) and non-carrier genotypes (AABB) are kept as expected by random chance. Since the sum of genotype frequencies has to be 1 and it has been reduced by eliminating co-carrier individuals, the frequencies need to be rescaled. Therefore, each genotype frequency is divided by the current sum of all genotype frequencies and this yields again the adjusted genotype frequencies to add up to a total of 1 (Supplementary Table S2). Since co-carriers have been removed, the allele frequencies in the population have changed, so a random sample of size N (38,341 as an example of a currently available cohort, 100,000 and 500,000) is taken from this population and is used to estimate the new allele frequencies and rebuild the expected counts following HWE. Expected and observed counts are collapsed in the four genotype categories mentioned in the previous section and compared using a χ^2 -test with 1 degrees of freedom. Simulations have also been performed

Table 1. DIDA variant combinations tested in the GE100K dataset.

Gene1	cDNA change1	Allele freq1 ^a	Gene2	cDNA change2	Allele freq2 ^a	Reported zygosity ^{b,c}	GE100K zygosity ^b	Obs ^d	Exp ^d	Diff ^d	p value
HAMP	c.212G>A	0.00334	HFE	c.845G>A	0.0735	Het/Hom	Het/Het(36)	36	35.84	0.16	0.9769
PRF1	c.272C>T	0.0415	STXBP2	c.1586G>C	0.0035	Het/Het	Het/Het(20)	20	21.9961	-1.9961	0.6559
PRF1	c.272C>T	0.0415	STXBP2	c.795-4C>T	0.0216	Het/Het	Het/Het(110); Hom/Het; Het/Hom(2)	113	133.1129	-20.1129	0.0631
PRF1	c.272C>T	0.0415	UNC13D	c.2896C>T	0.0069	Het/Het(2)	Het/Het(43)	43	42.937	0.063	0.9919
PRF1	c.272C>T	0.0415	UNC13D	c.3160A>G	0.0013	Het/Het	Het/Het(2)	2	8.1978	-6.1978	0.0237*

^aCalculated from 38,341 unrelated European samples in the GE100K dataset.

^bZygosity of each variant in the combination shown as Zygosity Var1/Zygosity Var2. Only observed zygosity is stated and they are separated by a semicolon “;” (i.e., for PRF1 c.272C>T and STXBP2 c.795-4C>T, there were no Hom/Hom individuals). Only when more than one individual is observed with a given zygosity, the number of individuals in parenthesis follows the zygosity.

^cReported zygosity was obtained from the original works reporting this variant combinations as disease-causing.

^dNumber of individuals in the genotype category of interest (Aa/aa + Bb/bb).

*P < 0.05.

without collapsing the nine genotype categories using a χ^2 -test with 6 degrees of freedom. Each set of parameters is simulated 1000 times and the percentage of times the χ^2 -test is significant ($p < 0.05$) represents the actual statistical power and is shown in Fig. 1.

We have analyzed the Genomics England 100,000 (GE100K) Genomes Project dataset consisting of WGS data from samples collected from the National Health Service hospitals along UK [8]. We applied a series of quality and ancestry filters (see Supplementary Material) that yielded a total of 38,341 unrelated samples with European ancestry.

RESULTS

We assessed the statistical power to discover associations between digenic combinations and disease, detected as a deficit of observed co-carrier individuals compared to the expected number in a healthy cohort by simulating different scenarios (Fig. 1). The main factors conditioning the power to detect significant associations are the sample size and allele frequencies which will determine the number of expected co-carriers. Also, the difference between the number of expected and observed co-carriers will be directly influenced by the penetrance of the digenic combination. High penetrance values should generate an important reduction in the number of observed co-carriers in the general population while in a scenario of low penetrance the number of affected co-carriers would be lower and differences between observed and expected would remain undetectable. As expected, simulations show a consistent increase of statistical power when sample size, penetrance, and allele frequencies increment. Results are consistent when genotype categories are not collapsed with only a mild statistical reduction in the case of smaller sample size and allele frequencies (Fig. 1). Simulations for $N = 100,000$ and $500,000$ show that statistical power of 80% or more can be achieved even with low allele frequencies and penetrance values. For $N = 38,341$, statistical power reaches a value of 80% for a penetrance higher than 0.2 and allele frequencies of more than 5%. For moderate allele frequencies (between 1% and 5%), penetrance should be higher than 0.5 while for lower frequencies for the two variants (lower than 1%) the power is limited.

Next, we compared the expected and observed frequencies of co-carriers for five variant combinations reported in the Digenic Diseases Database (DIDA) [6], in a subset of 38,341 GE100K unrelated European samples that we treat as a control dataset. These combinations showed an expected number of co-carriers of at least five individuals, allowing for statistical testing, thanks to the presence of one variant with a moderate frequency (4% and 7%) (Table 1 and Supplementary Table S3). Whereas for three of the combinations the number of expected co-carriers perfectly matched the observed one, suggesting that these may not be true disease causing combinations, two of them showed a notable decrease in the number of observed compared to expected co-carriers. The PRF1 c.272C>T and UNC13D c.3160A>G combination reaches a statistical significance of $p < 0.05$ for the χ^2 -test, with a reduction in the number of co-carriers that supports its pathogenic effect. This combination was previously reported to be a possible cause of familial hemophagocytic lymphohistiocytosis [9].

DISCUSSION

We have simulated the use of sequencing data to assess the power to detect digenic combinations associated with disease. We hypothesized that the number of individuals carrying likely pathogenic digenic combinations in the general population should be reduced in comparison to random expectation. We propose that our approach can be used to identify or rank digenic combinations, similar to other approaches that based in the analysis of population genetic variation generate information on individual gene properties such as Residual Variation Intolerance Score (RVIS) [10], or LoFtool [11], measuring the tolerance to functional variation.

Statistical power is highly dependent on the penetrance and allele frequency of the digenic combination, especially for smaller samples, while with larger datasets the power depends mainly on the penetrance even if the individual variants are found at very low frequencies. Associations involving genetic variants at allele frequencies of 1%–5% are detectable if the combination shows moderate to high penetrance as is commonly observed for single genetic variants in rare monogenic disorders. Also, note that this approach will be mostly powerful for situations where a double heterozygote has phenotypical effects, which is the most common scenario reported in DIDA. This can be concordant with combinations involving gain of function variants and/or loss of function variants in haploinsufficient genes. Of interest, interactions involving combinations of moderately low and low frequency variants may encompass cases including modifier genes, where a primary phenotype is determined by one gene but conditioned by the effect of a modifier gene [12].

We suggest considering the digenic model for undiagnosed rare disease cases. Restricting the search to pairs of candidate genes or interacting proteins can be a computationally affordable strategy in routine analysis. However, this approach would have the limitation of relying on prior functional knowledge, having a reduced effectiveness in uncovering novel digenic combinations. We believe that the current method will gain statistical power and be a valuable tool to reveal new hidden gene combinations underlying human disease with the advent of new sequencing efforts that will offer the availability of hundreds of thousands of human genomes.

CODE AVAILABILITY

Code on the simulations is available upon request. Data and code related to GE100K are available upon acceptance by Genomics England.

REFERENCES

- Frésard L, Montgomery SB. Diagnosing rare diseases after the exome. Cold Spring Harbor Molecular Case Studies. Cold Spring Harbor Laboratory Press; 2018, Vol. 4.
- Wright CF, FitzPatrick DR, Firth HV. Paediatric genomics: diagnosing rare disease in children. *Nat Rev Genet* [Internet]. 2018;19:253–68. <https://pubmed.ncbi.nlm.nih.gov/29398702> Accessed 22 Dec 2021
- Boycott KM, Hartley T, Biesecker LG, Gibbs RA, Innes AM, Riess O, et al. A diagnosis for all rare genetic diseases: the horizon and the next frontiers. *Cell*. 2019;177:32–7.
- Katsanis EN, Robinson JF. Oligogenic disease. In: Speicher MR, Motulsky AG, Antonarakis SE, editors. *Vogel and Motulsky's human genetics: problems and approaches*. 4th ed. Berlin, Heidelberg: Springer; 2010. p. 243–62.
- Schäffer AA. Digenic inheritance in medical genetics. *J Med Genet* [Internet]. 2013;50:641–52. <https://pubmed.ncbi.nlm.nih.gov/23785127/> Accessed 22 Dec 2021.
- Gazzo AM, Daneels D, Cilia E, Bonduelle M, Abramowicz M, Van Dooren S, et al. DIDA: a curated and annotated digenic diseases database. *Nucleic Acids Res* [Internet] 2016;44:D900–7. <https://pubmed.ncbi.nlm.nih.gov/26481352/> Accessed 22 Dec 2021.
- Gauderman WJ. Sample size requirements for association studies of gene-gene interaction. 2002. <https://academic.oup.com/aje/article/155/5/478/171660>. Accessed 25 May 2022
- Genomics England [Internet]. 2019. <http://www.genomicsengland.co.uk>. Accessed 15 Nov 2019.
- Zhang K, Chandrakasan S, Chapman H, Valencia CA, Husami A, Kissell D, et al. Synergistic defects of different molecules in the cytotoxic pathway lead to clinical familial hemophagocytic lymphohistiocytosis. *Blood* [Internet] 2014;124:1331–4. <https://pubmed.ncbi.nlm.nih.gov/24916509/> Accessed 22 Dec 2021.
- Gussow AB, Petrovski S, Wang Q, Allen AS, Goldstein DB. The intolerance to functional genetic variation of protein domains predicts the localization of pathogenic mutations within genes. *Genome Biol* [Internet]. 2016. Vol. 17. <https://pubmed.ncbi.nlm.nih.gov/26781712/>. Accessed 22 Dec 2021.
- Fadista J, Oskolkov N, Hansson O, Groop L. LoFtool: a gene intolerance score based on loss-of-function variants in 60 706 individuals. *Bioinforma* [Internet]. 2017;33:471–4. <https://pubmed.ncbi.nlm.nih.gov/27563026/> Accessed 22 Dec 2021.
- Génin E, Feingold J, Clerget-Darpoux F. Identifying modifier genes of monogenic disease: strategies and difficulties. *Hum Genet* [Internet]. 2008;124:357–68. <https://pubmed.ncbi.nlm.nih.gov/18784943/> Accessed 22 Dec 2021.

ACKNOWLEDGEMENTS

This research was made possible through access to the data and findings generated by the 100,000 Genomes Project; <http://www.genomicsengland.co.uk>.

AUTHOR CONTRIBUTIONS

NMR, HL, and FC conceived and designed the study. GE provided the data and the platform used for the analyses. NMR, HL, OL, JIA, and FC performed the analysis. All the authors contributed to manuscript writing.

FUNDING

This study was funded by grants RTI2018-096824-B-C22 (FC), PID2021-125106OB-C32 (FC), RTI2018-096824-B-C21 (JIA) and PID2021-125106OB-C31 (JIA) funded by MCIN/AEI /10.13039/501100011033/ and FEDER Una manera de hacer Europa; Direcció General de Recerca- Generalitat de Catalunya (2017SGR-702) (FC); and CERCA Programme/Generalitat de Catalunya (JIA). NMR was supported by grant 2021 FL_B_00296 from Agència de Gestió d'Ajuts Universitaris i de Recerca, Generalitat de Catalunya. This research was made possible through access to the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100,000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support.

COMPETING INTERESTS

The authors declare no competing interests.

ETHICS APPROVAL

Genomics England has approval from the HRA Committee East of England – Cambridge South (REC Ref 14/EE/1112).

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41431-022-01191-x>.

Correspondence and requests for materials should be addressed to Hafid Laayouni or Ferran Casals.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons

Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2022

GENOMICS ENGLAND RESEARCH CONSORTIUM

J. C. Ambrose⁸, P. Arumugam⁸, E. L. Baple⁸, M. Bleda⁸, F. Boardman-Pretty^{8,9}, J. M. Boissiere⁸, C. R. Boustred⁸, H. Brittain⁸, M. J. Caulfield^{8,9}, G. C. Chan⁸, C. E. H. Craig⁸, L. C. Daugherty⁸, A. de Burca⁸, A. Devereau⁸, G. Elgar^{8,9}, R. E. Foulger⁸, T. Fowler⁸, P. Furió-Tari⁸, A. Giess⁸, J. M. Hackett⁸, D. Halai⁸, A. Hamblin⁸, S. Henderson^{8,9}, J. E. Holman⁸, T. J. P. Hubbard⁸, K. Ibáñez^{8,9}, R. Jackson⁸, L. J. Jones^{8,9}, D. Kasperaviciute^{8,9}, M. Kayikci⁸, A. Kousathanas⁸, L. Lahnstein⁸, K. Lawson⁸, S. E. A. Leigh⁸, I. U. S. Leong⁸, F. J. Lopez⁸, F. Maleady-Crowe⁸, J. Mason⁸, E. M. McDonagh^{8,9}, L. Moutsianas^{8,9}, M. Mueller^{8,9}, N. Murugaesu⁸, A. C. Need^{8,9}, C. A. Odhams⁸, A. Orioli⁸, C. Patch^{8,9}, D. Perez-Gil⁸, M. B. Pereira⁸, D. Polychronopoulos⁸, J. Pullinger⁸, T. Rahim⁸, A. Rendon⁸, P. Riesgo-Ferreiro⁸, T. Rogers⁸, M. Ryten⁸, K. Savage⁸, K. Sawant⁸, R. H. Scott⁸, A. Siddiq⁸, A. Sieghart⁸, D. Smedley^{8,9}, K. R. Smith^{8,9}, S. C. Smith⁸, A. Sosinsky^{8,9}, W. Spooner⁸, H. E. Stevens⁸, A. Stuckey⁸, R. Sultana⁸, M. Tanguy⁸, E. R. A. Thomas^{8,9}, S. R. Thompson⁸, C. Tregidgo⁸, A. Tucci^{8,9}, E. Walsh⁸, S. A. Watters⁸, M. J. Welland⁸, E. Williams⁸, K. Witkowska^{8,9}, S. M. Wood^{8,9} and M. Zarowiecki⁸

⁸Genomics England, London, UK. ⁹William Harvey Research Institute, Queen Mary University of London, London EC1M 6BQ, UK.